A validated capillary electrophoresis method for simultaneous determination of ezetimibe and atorvastatin in pharmaceutical formulations  by AlShehri, Mona M.
Saudi Pharmaceutical Journal (2012) 20, 143–148King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEA validated capillary electrophoresis method
for simultaneous determination of ezetimibe
and atorvastatin in pharmaceutical formulationsMona M. AlShehri *Pharmaceutical Chemistry Department, Pharmacy College, King Saud University, P.O. Box 16460, Riyadh 11464, Saudi ArabiaReceived 4 July 2011; accepted 16 September 2011
Available online 24 September 2011*
E
13
El
Pe
doKEYWORDS
Ezetimibe;
Atorvastatin;
Capillary electrophoresis;
Diode array detector;
TabletsTel.: +966 505477243; fax:
-mail addresses: malshihri@
19-0164 ª 2011 King Saud
sevier B.V. All rights reserve
er review under responsibilit
i:10.1016/j.jsps.2011.09.005
Production and h+966 12
ksu.edu.s
Universit
d.
y of King
osting by EAbstract A simple, precise, and sensitive capillary electrophoresis technique coupled with a diode
array detector has been developed for the separation and simultaneous determination of ezetimibe
and atorvastatin in pharmaceutical formulations. Separation of both ezetimibe and atorvastatin
was achieved utilizing fused silica capillary (58 cm · 75 lm ID) and background electrolyte solution
that consisted of phosphate buffer (2.5 mM, pH 6.7): methanol (70:30 v/v). The proposed method
was validated by testing its speciﬁcity, linearity, precision, accuracy, recovery, and detection limit/
quantitation limit values. The method was linear over the range 2.5–50 lg/ml for ezetimibe
(r= 0.9992) and 1–100 lg/ml for atorvastatin (r= 0.9999). Within-day and between-day RSD
for ezetimibe and atorvastatin were 65.6% and 62.9%, respectively. The detection limit was
0.07 lg/ml for ezetimibe and 0.06 lg/ml for atorvastatin. The validated method was successfully
employed for the determination of ezetimibe and atorvastatin in tablets with no interfering peaks
from common pharmaceutical excipients. The percentage recoveries of the two drugs from their
tablets were 99.80 ± 1.76 and 100.19 ± 1.83, respectively.
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lsevier1. Introduction
Ezetimibe (1-(4-ﬂurophenyl)-3(R)-[3(S)-(4-ﬂurophenyl)-3-
hydroxypropyl]-4(S) (4-hydroxyphenyl) azetidin-2-one), which
belongs to a group of selective and very effective 2-azetidione
cholesterol absorption inhibitors, acts at the level of choles-
terol entry into enterocytes. It prevents transport of cholesterol
through the intestinal wall by selectively blocking the absorp-
tion of cholesterol from dietary and biliary sources. This
reduces the overall delivery of cholesterol to the liver, thereby
promoting the synthesis of LDL receptors and a subsequent
reduction in the serum LDL-C (Catapano, 2001; Heek and
Davis, 2002; Bruckert et al., 2003).
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d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) car-
bonyl]-1H-pyrrole-1-heptanoic acid, a trihydrate of calcium
salt (2:1). Atorvastatin is an inhibitor of 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG-CoA) reductase. This enzyme cat-
alyzes the conversion of HMG-CoA to mevalonate, an early
and rate-limiting step in cholesterol biosynthesis (Lea and
McTavish, 1997; Beringer, 2005). The typical dose of atorva-
statin calcium is 10–80 mg per day and it reduces 40–60%
LDL (Page et al., 2002).
Combining the different mechanisms of action of these
agents appears to provide substantial reductions in LDL-C,
with additional favorable changes in total cholesterol, triglyc-
erides, and HDL-C. Clinical studies have shown that
co-administration of ezetimibe plus atorvastatin was signiﬁ-
cantly more effective at reducing LDL-C concentrations than
ezetimibe or atorvastatin alone. Ezetimibe plus the starting
dose of atorvastatin (10 mg) lowered direct LDL-C as effec-
tively as the maximum dose of atorvastatin (80 mg) alone, re-
duced triglycerides by a similar amount, but provided
signiﬁcantly greater increase in HDL-C (9% versus 3%).
Moreover, co-administration of ezetimibe with low dose ator-
vastatin was a well tolerated option to high dose atorvastatin
monotherapy (Ballantyne et al., 2003, 2004; Conard et al.,
2008a,b; Kaliappan et al., 2011).
There is an urgent need to develop an analytical method for
the simultaneous analysis of ezetimibe and atorvastatin in
pharmaceutical dosage forms due to the continuous increase
in clinical use of these two agents as a combination.
A number of methods based on spectrophotometry
( Sonawane et al., 2007; Baldha et al., 2009; Godse et al.,
2009; Maher et al., 2011), densitometry (Dhaneshwar et al.,
2007), and HPLC (Qutab et al., 2007; Seshachalam and Kotha-
pally, 2008; Sama et al., 2010; Bhatt et al., 2010) were reported
for the simultaneous determination of ezetimibe and atorva-
statin in pharmaceutical preparations.
There is no reported method available in the literature for
the simultaneous determination of ezetimibe and atorvastatin
by capillary electrophoresis (CE).
CE has distinct advantages over other techniques in terms
of fast analysis times, smaller quantities of solutions and min-
imal organic usage, and thus overall lower consumable
expenses can be attained. More importantly, CE can produce
much deﬁned peaks with a high degree of resolution and the
separation is achievable in a wide pH range.
Therefore, a simple, precise, and sensitive capillary electro-
phoresis method was developed in this study for the separation
and simultaneous quantitation of the two drugs in tablets.2. Experimental
2.1. Chemicals and reagents
Ezetimibe, atorvastatin calcium, and losartan, as internal stan-
dard (IS), were kindly obtained from the Drug Control Centre,
Riyadh, Saudi Arabia. Ezetrol tablets 10 mg (MSD–Scher-
ing-Plough) and Lipitor tablets 10, 20, 40 mg (Parke-Davis)
were purchased from the local market. HPLC grade methanol,
analytical grade disodium hydrogen phosphate, and sodium
dihydrogen phosphate were obtained from Merck (Germany).
Deionized water was used throughout the experiments.2.2. Electrophoretic instrumentation and conditions
The employed CE system consisted of an Agilent capillary elec-
trophoresis instrument (Agilent Technologies, Germany)
equipped with a diode array detector (DAD) and a data han-
dling system comprised of an HP computer and Agilent Chem
station software. Detection was performed at 210 nm. A deac-
tivated fused silica capillary was obtained from Agilent Tech-
nologies and had the following dimensions 67 cm total length,
58 cm effective length, and 75 lm ID. The temperature of the
capillary and the samples was maintained at 24 C. The back-
ground electrolyte solution (BGE) consisted of phosphate buf-
fer (2.5 mM, pH 6.7):methanol (70:30 v/v). Samples were
injected into the capillary by pressure at the anodic side at
50 mbar for 10 s. The electrophoresis was carried out by apply-
ing 25 kV voltage to the capillary, with the cathode being at the
detector end. The capillary was washed between run with
deionized water (3 min), then equilibrated with the running
buffer (5 min), to ensure reproducibility of the assay. The solu-
tions were ﬁltered through aMillipore membrane ﬁlter (0.2 lm)
from Nihon, Millipore (Japan), before injection.
2.3. Preparation of stock and standard solutions
Stock solutions containing 1 mg/ml of ezetimibe and atorva-
statin were prepared in methanol. The internal standard (IS)
losartan was prepared in water to give a concentration of
1 mg/ml and was further diluted with water to get the working
solution 0.2 mg/ml. Aliquots of the standard stock solutions of
ezetimibe and atorvastatin were transferred into 10 ml volu-
metric ﬂasks, 1 ml of IS working solution was added to each
ﬂask, then completed to the mark with the BGE to yield ﬁnal
concentrations of 2.5, 5, 10, 20, 40, and 50 lg/ml for ezetimibe,
and 1, 10, 20, 50, 80, and 100 lg/ml for atorvastatin. Triplicate
injections of each concentration were performed. The peak-
area ratio of each concentration to the IS (As/Ast) against
the corresponding standard concentration was plotted to con-
struct the calibration curves, and the corresponding regression
equations were derived.
2.4. Analysis of laboratory-made mixtures
Stock solutions of ezetimibe and atorvastatin (equivalent to
1 mg/ml) were prepared in methanol. Aliquots of the standard
stock solutions of both drugs were transferred into 10 ml vol-
umetric ﬂasks, 1 ml of the IS working solution was added to
each ﬂask, then completed to the mark with the BGE to yield
different concentrations ratios of ezetimibe:atorvastatin (1:1,
1:2, 1:4). Triplicate injections from each solution were made.
The peak area ratio of each concentration to the IS was calcu-
lated. The concentration of each drug is obtained using the
corresponding regression equations.
2.5. Analysis of tablets
Ten tablets of each preparation (Ezetrol 10 mg, and Lipitor
10, 20, 40 mg) were weighed and powdered. Accurately
weighed portions equivalent to one tablet content (10 mg eze-
timibe, and 10, 20, 40 mg atorvastatin) were transferred into
each of 10 ml volumetric ﬂasks containing 5 ml methanol.
The solutions were stirred and sonicated for 20 min, then made
up to volume with methanol, mixed well, and centrifuged at
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transferred to 10 ml volumetric ﬂasks, 1 ml of the IS working
solution was added to each ﬂask, and completed to volume
with the BGE, to yield different concentrations ratios of eze-
timibe:atorvastatin (1:1, 1:2, 1:4). Triplicate injections from
each solution were made. The peak area ratio of each concen-
tration to the IS was calculated. The concentration of each
drug is obtained using the corresponding regression equations.
3. Results and discussion
The electrophoretic parameters were preliminarily optimized
to develop a capillary electrophoresis method for the simulta-
neous determination of ezetimibe and atorvastatin with short
analysis time and acceptable resolution.
3.1. Method optimization
The choice of the electrolyte system (BGE) is still one of the
key problems in the application of electrophoresis in analytical
chemistry since its role is very complex. The main purposes of
a BGE are to provide the transport of electric current and the
separation of the analytes. But if an electric current passes
through a BGE, some additional phenomena occur, such as
the electroosmotic ﬂow (EOF), which plays an important role
in the electrophoretic processes. The BGE should primarily
provide an appropriate migration of the analytes in a reason-
able time with no peak broadening and migration interferences
(Beckers and Bocek, 2003). Therefore, the most important
parameters that affect the BGE were examined in order to
reach the most suitable system for the optimum separation
of the two drugs under study, and the results will be discussed
as follow:
3.1.1. Effect of pH
The pH is of key importance for electromigration in systems
with weak electrolytes (weak bases and weak acids). The pH
of the BGE has to be regulated in order to keep the migration
velocity of weak electrolyte and the velocity of the EOF con-
stant. In that way, a stable and reproducible migration behav-
ior of the analytes can be obtained. The effective mobility (the
electromigration of a partially ionized substance) for weak
anionic and cationic species is strongly dependent on their
pK values related to the pH of the BGE. However, it should
be emphasized, that even substances with zero effective
mobility may move in the capillary due to the EOF, and this
EOF is also strongly dependent on the pH of the BGE used
(Beckers and Bocek, 2003).The pH in values from 5–10
were chosen for the study. The selected buffer was phosphate
buffer. It is studied in three selected concentrations (1, 2.5,
and 5 mM) under constant instrumentation conditions
(voltage, injection time, temperature, pressure, and wave
length). Phosphate buffer (2.5 mM, pH 6.7) has a good resolu-
tion and analysis time in comparison to the other electrolyte
systems.
3.1.2. Effect of buffer concentration
Different BGEs have been tested. The best results considering
selectivity, reproducibility, baseline separation, and current
performance were obtained with sodium phosphate buffer
(pH 6.7). Keeping other parameters constant (pH 6.7, 25 kV,
24 C), the buffer concentration varied from 1 to 5 mM wasstudied. Increasing in migration times was observed when
the buffer concentration increased. The resolution of ezetimibe
and atorvastatin increased as the buffer concentration in-
creased, but long migration times were observed at the buffer
concentrations more than 2.5 mM. Therefore, 2.5 mM sodium
phosphate buffer (pH 6.7) was selected as optimum BGE.
3.1.3. Effect of organic modiﬁer concentration
The most obvious advantage from the addition of organic sol-
vents into the run buffer is that it would extend the range of
analytes that can be investigated, due to an enhancement in
the solubility of various substances. Another major advantage
is the potential increase in separation selectivity compared to
the aqueous CE separations through changes in the physico-
chemical properties, such as changes in acid–base properties
of the analytes, viscosity and dielectric constant of the separa-
tion medium, as well as interactions between analytes and sol-
vent. Other advantages of organic solvents include the
capability of signiﬁcantly reducing the analysis time by
employing relatively high applied voltages, since most organic
solvents have lower dielectric constants compared to water
and, thus, relatively high voltages can be applied without caus-
ing any signiﬁcant band broadening due to Joule heating
(Huie, 2003).
The organic modiﬁer used in this study is methanol. The
amount added to the phosphate buffer ranges from 20% to
60%. It causes an increase in the separation selectivity and res-
olution factor (Rs) between the two drugs. Although the Rs
factor is increased, late migration times were observed at a
concentration more than 50%. Therefore, the 30% methanol
was chosen as the optimum concentration.
3.1.4. Effect of applied voltage
The applied voltage can affect the efﬁciency of analysis since
the resolution of compounds is directly proportional to it
(McLaughlin et al., 1992). The applied voltage was gradually
increased from 15 to 30 kV. The best resolution was observed
when applying a voltage of 25 kV. At 15 kV, no signals were
detected. Further increase in the applied voltage of more than
25 kV resulted in a decreased resolution.
Finally, the separation of ezetimibe and atorvastatin was
carried out under the above optimized conditions and the
migration times were 8.59 ± 0.03 and 13.21 ± 0.20 min for
ezetimibe and atorvastatin, respectively (Fig. 1).
3.2. Method validation
The main objective of validation of an analytical procedure is
to demonstrate that the procedure is suitable for its intended
purpose. Therefore, the capillary electrophoresis method
developed for the simultaneous determination of ezetimibe
and atorvastatin in this study was validated according to the
ICH guidelines for its speciﬁcity, linearity, range, accuracy,
precision, detection limit and quantitation limit (ICH, 2005).
3.2.1. Speciﬁcity
Speciﬁcity is the ability to assess unequivocally the analyte in
the presence of components which may be expected to be pres-
ent. These might include impurities, degradation product, and
excipients. The electropherogram in Fig. 1, demonstrates the
speciﬁcity of the method. There are no peaks detected at the
migration times of both drugs and internal standard from
Figure 1 Electropherogram of 20 lg/ml ezetimibe (1), 50 lg/ml atorvastatin (2), and 20 lg/ml IS (3).
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drugs. Also, peak purity tests may be useful to show that the
analyte peak is not attributable to more than one component.
Peak purities of ezetimibe and atorvastatin were evaluated by
the use of the DAD detector.
3.2.2. Linearity
The linearity of the method was evaluated by constructing six-
point calibration curves. Excellent linearity was observed over
the concentration range of 2.5–50 lg/ml for ezetimibe and
1.0–100 lg/ml for atorvastatin. The peak area ratios of the
drugs to the IS (As/Ast) versus concentrations were plotted
and a linear least-square regression analysis was conducted
to determine the slope, intercept, and correlation coefﬁcient
(r) to demonstrate the linearity of the method. The correlation
coefﬁcient (r) was found to be 0.9992 and 0.9999 for ezetimibe
and atorvastatin, respectively. The linear regression analysis
data are summarized in Table 1.
3.2.3. Range
The speciﬁed range is normally derived from the linearity stud-
ies and depends on the intended application of the procedure.Table 1 Validation parameters for the determination of
ezetimibe and atorvastatin by the proposed method.
Parameter Ezetimibe Atorvastatin
Concentration range (lg/ml) 2.5–50 1.0–100
Intercept (b) 0.005 0.012
Slope (m) 0.018 0.033
Correlation coeﬃcient (r) 0.9992 0.9999
Sb 0.0099 0.0112
Sm 0.0003 0.0001
Sx/y 0.0157 0.0178
DL (lg/ml) 0.07 0.06
QL (lg/ml) 0.25 0.20
Sb = standard deviation of intercept.
Sm = standard deviation of slope.
Sx/y = Standard deviation of the residual.The developed method provided an excellent linearity, accu-
racy, and precision when applied to the samples containing
amounts of ezetimibe and atorvastatin within or at the
extremes of the speciﬁed range of this method (2.5–50 lg/ml
for ezetimibe and 1.0–100 lg/ml for atorvastatin).
3.2.4. Accuracy and precision
Accuracy and precision should be reported as percentage error
(%E) and relative standard deviation (%RSD), respectively,
and should be established across the range of the developed
method. They were determined by the analysis of three differ-
ent concentrations for each drug. The within-day accuracy and
precision were assessed from the results of the analysis of the
three concentrations on a single day. The between-day accu-
racy and precision were determined from the same three con-
centrations analyzed on three consecutive days (Table 2).
3.2.5. Detection limit
The detection limit (DL) is the lowest amount of analyte in a
sample which can be detected but not quantitated. Several ap-
proaches for determining the DL are present (visual evalua-
tion, signal-to-noise, standard deviation of the intercept and
the slope). The standard deviation of the intercept and the
slope approach was used to determine the DL in this study.
The detection limit was 0.07 lg/ml for ezetimibe and 0.06 lg/
ml for atorvastatin (Table 1).
3.2.6. Quantitation limit
The quantitation limit (QL) is the lowest amount of analyte in
a sample which can be quantitatively determined. The ap-
proach used in determining the DL, was also used for deter-
mining the QL. The quantitation limits of ezetimibe and
atorvastatin were 0.25 and 0.20 lg/ml, respectively (Table 1).
3.2.7. Stability in solutions
Investigation of the stability was established for the 10 lg/ml
solution of ezetimibe and atorvastatin kept at room tempera-
ture ﬁve days. Both drugs were stable under these conditions.
No additional peaks were found in the electropherograms
throughout the analysis time, indicating the stability of both
drugs in the sample solution.
Table 2 Accuracy and precision data for ezetimibe and atorvastatin.
Analyte Added conc. (lg/ml) Found conc. (lg/ml) (mean ± SD) RSD (%) Error (%)
Within-day
Ezetimibe 8.50 8.54 ± 0.002 1.2 0.56
21.25 21.40 ± 0.007 1.7 0.70
34.00 33.64 ± 0.009 1.5 1.04
Atorvastatin 20.40 20.56 ± 0.014 2.0 0.18
51.00 50.75 ± 0.038 2.3 0.43
81.60 80.78 ± 0.049 1.8 0.30
Between-day
Ezetimibe 8.50 8.49 ± 0.006 3.6 0.43
21.25 21.12 ± 0.015 3.7 0.59
34.00 33.97 ± 0.035 5.6 0.07
Atorvastatin 20.40 20.24 ± 0.019 2.9 1.44
51.00 50.45 ± 0.032 1.9 0.17
81.60 80.87 ± 0.028 1.0 0.35
Figure 2 Electropherogram of tablet solution of 17 lg/ml ezetimibe (1), 48 lg/ml atorvastatin (2), and 20 lg/ml IS (3).
Table 3 Analysis of ezetimibe and atorvastatin in tablets by the proposed method.
Mixturea
Ezetimibe:Atorvastatin
Added conc.
(lg/ml)
Ezetimibe Atorvastatin
Found conc. (lg/ml)
(mean ± SD)
Recovery (%) Found conc. (lg/ml)
(mean ± SD)
Recovery (%)
1:1 17:24 16.62 ± 0.28 97.76 23.60 ± 0.16 98.33
1:2 17:48 17.14 ± 0.72 100.82 48.96 ± 0.40 102.00
1:4 17:96 17.14 ± 0.50 100.82 96.24 ± 1.16 100.25
Average 99.80 ± 1.76 100.19 ± 1.83
a Laboratory-made mixture.
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The proposed method was applied for the determination of
ezetimibe and atorvastatin in their pharmaceutical formula-
tions (Fig. 2) and the results are shown in Table 3.4. Conclusion
The developed method is considered as the ﬁrst method for
simultaneous separation and quantitation of ezetimibe and
atorvastatin by capillary electrophoresis. It is a simple, rapid,
148 M.M. AlShehriand sensitive procedure and was successively applied for the
quantitation of the two drugs in tablets. The various validation
characteristics were applied and determined to assure the suit-
ability of the method. It was found that the method is valid
and suitable for its intended purpose which is the simultaneous
determination of the studied drugs in tablets.Acknowledgment
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